Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Although Sanofi’s management believes that the expectations reflected ... and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business ...

French Economy, Finance and Industry Minister Antoine Armand attends a joint press conference on the government's role ...

After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...